Stručni rad
https://doi.org/10.20471/acc.2024.63.s2.12
Current State of Evidence and Practice of Prostate-Specific Membrane Antigen (Psma) Imaging Across the Prostate Cancer Clinical Landscape – Oncologist Perspective
Antonela Njavro
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Jure Murgić
orcid.org/0000-0001-8152-0494
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
*
Blanka Jakšić
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Marin Prpić
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
Angela Prgomet Sečan
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Dražen Huić
; Clinical Department of Nuclear Medicine and Radiation Protection, Zagreb University Hospital Centre, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia
Dinko Franceschi
; Department of Radiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA
Ana Fröbe
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
* Dopisni autor.
Sažetak
Prostate cancer (PC) is the most widespread malignancy in men worldwide and
the third leading cause of cancer-related death. Accurate diagnostic and staging procedures are key for
therapy success and personalized treatment in all stages of PC. Prostate cancer-specific positron emission
tomography-computed tomography (PET/CT) is able to detect disease sites in both localized and
recurrent PC, at serum levels of prostate specific antigen (PSA) that are lower compared with those
detected by conventional imaging. Currently, the backbone of nuclear medicine staging in PC is based on
prostate-specific membrane antigen (PSMA) PET/CT, given the numerous advantages of PSMA over
other tracers used for PC molecular imaging. In this free-style narrative review, the historic perspective,
literature, clinical utility, and practice patterns of PSMA PET/CT in PC are discussed and key points
summarized for busy oncologists with an interest in PC.
Ključne riječi
PSMA; Staging; Restaging; Biochemical failure; Theranostics; PET/CT; New generation imaging; Prostate cancer
Hrčak ID:
323261
URI
Datum izdavanja:
30.4.2024.
Posjeta: 0 *